CARA.Cara Therapeutics, INC

Form 4: Tvardi Therapeutics CEO Granted Stock Options

Sentiment:

SEC Form 4

📋All filings for Cara Therapeutics, INC
🔒Login to Follow

Imran Nizamudin Alibhai, CEO of Tvardi Therapeutics, receives stock options for 182,320 shares.

Summary

  • Imran Nizamudin Alibhai, the CEO of Tvardi Therapeutics, was granted employee stock options on April 17, 2025.
  • The options are for 182,320 shares of common stock at an exercise price of $17.04.
  • 25% of the options will vest on April 17, 2026, with the remaining options vesting monthly over the following 36 months, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The granting of stock options is generally viewed positively as it aligns management's interests with shareholders, but it also represents potential future dilution.

Positives

  • The granting of stock options aligns the CEO's interests with those of the shareholders.
  • The vesting schedule incentivizes long-term commitment from the CEO.

Future Outlook

The vesting schedule suggests a commitment to long-term value creation for Tvardi Therapeutics.

Industry Context

Granting stock options to executives is a common practice in the biotech industry to incentivize performance and align management's interests with shareholders.

Stakeholder Impact

  • Shareholders may experience dilution if the options are exercised.
  • Employees may be motivated by the CEO's incentivized performance.

Key Dates

DateDescription
04/17/2025Date of the stock option grant.
04/17/2026Date when 25% of the stock options begin to vest.
04/16/2035Expiration date of the stock options.

Keywords

stock options, Tvardi Therapeutics, CEO, Imran Nizamudin Alibhai, equity, vesting

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.